Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...

Mind-body therapies like meditation, psychotherapy, and deep breathing may help reduce stress levels, potentially reducing ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...

Adam Friedman, MD: Hello, and welcome to Medscape Care Cues. I'm Dr Adam Friedman and I'm joined by my good friend and colleague, Dr Shawn Kwatra. Welcome, Shawn. Shawn G. Kwatra, MD: Thanks so ...

Analyst Silvan Tuerkcan of JMP Securities reiterated a Buy rating on Allakos (ALLK – Research Report), with a price target of $3.00.Stay Ahead ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts, indicating potential effectiveness of briquilimab in treating chronic spontaneous urticaria (CSU).

Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...

Wedbush lowered the firm’s price target on Blueprint Medicines (BPMC) to $124 from $135 and keeps an Outperform rating on the shares. The firm ...

Despite positive preliminary data from its early stage study of treating hives, Jasper Therapeutics Inc. saw its stock drop dramatically on Jan. 8. Results were from the ongoing phase Ib/IIa study of ...

Opens in a new tab or window Chronic urticaria (CU) is a common skin condition characterized by the spontaneous development of angioedema. A person with CU may experience chronic spontaneous ...

Despite the promising clinical data, the over 40% drop in Jasper's stock price indicates that investors may have reservations about the study results or the company's future prospects. As the market ...